MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why NUVB Stock surged +3.92% Today — RQD Quant Desk Flash
$4.77 +3.92% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.79
Nuvation Bio Inc. (Class A) (NUVB) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $1.67B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.79 (+0.52%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-13% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NUVB)Realized 20D OHLCV Swing Band: ±10.8%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY NUVB SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (38% of score)
20D Institutional Volume Accumulation (±10.8% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)
Altman Z-Score 0.76 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$5.00-11% Next Q
37
Q2 (-2Q)Grade E$4.45+2.7% Next Q
34
Q3 (-1Q)Grade E$4.57+4.4% Next Q
32
CurrentGrade E$4.77-9.8% Hist 90D α
29
Trajectory: E (37) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NUVB Turnaround Squeeze
While NUVB currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.63) and Max Pain ($5.01) forces dealer call-delta covering toward $10.24.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NUVB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NUVB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NUVB Stock surged +3.92% Today — RQD Quant Desk Flash
Nuvation Bio Inc. (Class A) (NUVB) surged +3.92% to $4.77, trading at 15% of its 52-week range ($3.92 – $9.75). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 15% of its 52-week range ($3.92 – $9.75) with RSI-14 at 42.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.8% around $4.77 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live NUVB Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NUVB)
- ✓Walkthrough of NUVB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NUVB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +7.19%📐 HORIZONTAL RANGE
2026-10-30O $4.75H $4.80L $4.60C $4.77VOL 5.06M
RES: $8.86SUP: $4.22SMA50: $5.63SMA200: $5.40
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NUVB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NUVB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NUVB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NUVB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NUVB)
Health Care Rank #951 of 1016
⚔️ ANIP vs NUVB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NUVB vs. ANIP, CMPS, RARE, STOK)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Nuvation Bio Inc. (Class A) (NUVB) ranks #951 by composite RQD confidence (29/100, grade E) and #290 by equity capitalization ($1.67B). Within this direct 5-issuer industry benchmark cohort, ANIP leads on earnings valuation at 21.5x trailing P/E, while ANIP leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. ANIP currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with NUVB at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NUVB
ACTIVE
Nuvation Bio Inc. (Class A) | E | 29/100 | — | — | -35.0% | +3.92% | $1.67B | Benchmark Subject |
| ANIP ANI Pharmaceuticals Inc. | B- | 70/100 | 21.5x | — | 16.0% | +2.02% | $1.68B | /anip-vs-nuvb → |
| CMPS COMPASS Pathways Plc American Depository Shares | D- | 37/100 | — | — | -35.0% | -0.73% | $1.69B | /cmps-vs-nuvb → |
| RARE Ultragenyx Pharmaceutical Inc. | E | 26/100 | — | — | -35.0% | -2.44% | $1.65B | /rare-vs-nuvb → |
| STOK Stoke Therapeutics Inc. | C- | 59/100 | — | — | -6.1% | -0.23% | $1.70B | /stok-vs-nuvb → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001811063In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nuvation Bio Inc. (Class A) (NUVB) reported GAAP revenue of $62.9M (+699.0% vs. FY2024 revenue of $7.9M ) , GAAP net income of -$204.6M, operating cash flow of -$173.4M, and free cash flow of -$173.4M (-33.0% YoY). On the balance sheet, NUVB closed FY2025 with $594.8M in total assets against $0 in total debt (Altman Z-Score: 0.76, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $62.9M | -$204.6M | -$173.4M | -$173.4M | $594.8M | — |
| FY2024 (FY) | 2024-12-31 | $7.9M | -$567.9M | -$130.4M | -$130.4M | $540.6M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$75.8M | -$68.0M | -$68.0M | — | — |
3. NUVB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NUVB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Nuvation Bio Inc. (Class A) (NYSE: NUVB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $4.77 (+3.92% 1D, market cap $1.67B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NUVB ranks #951 in composite RQD confidence.
How does NUVB compare to ANIP and CMPS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NUVB carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ANIP (ANI Pharmaceuticals Inc.) holds a B- grade (70/100 RQD, P/E 21.5x, ROIC 16.0%, cap $1.68B) and CMPS (COMPASS Pathways Plc American Depository Shares) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.69B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NUVB?
Per NUVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001811063), Nuvation Bio Inc. (Class A) generated $62.9M in revenue (+699.0% YoY), -$204.6M in net income, and -$173.4M in free cash flow against $594.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NUVB trading relative to its 50-day, 200-day, and 52-week technical levels?
NUVB last traded at $4.77 (+3.92% on volume of 6,497,097 shares), positioning the stock -15.28% below its 50-day simple moving average ($5.63) and -11.67% below its 200-day simple moving average ($5.40). Across its 52-week range of $3.92 to $9.75, NUVB sits at the 14.6% percentile with a 14-day RSI of 42.2 (NEUTRAL RANGE) and an implied next-earnings move of ±10.8% ($4.25 to $5.29).
NUVB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NUVB stock moving today?
Why NUVB Stock surged +3.92% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.